Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Post by SkyLight8on Aug 23, 2021 7:24pm
121 Views
Post# 33752832

CUMULATIVE MARKET VALUE OVER $200 BILLION Planned* pharmacok

CUMULATIVE MARKET VALUE OVER $200 BILLION Planned* pharmacokCUMULATIVE MARKET VALUE OVER $200 BILLION Planned* pharmacokinetic (“PK”) studies will evaluate ability to improve quantity of drug delivered and speed with which it is delivered, in all of these areas: Details to be announced and subject to change and scheduling (1) https://www.globenewswire.com/en/news-release/2021/06/01/2239293/0/en/Global-Cannabidiol-CBD-Market-Size-to-Grow-at-a-CAGR-of-51-from-2021-to-2030.html (2) https://www.globenewswire.com/en/news-release/2021/05/17/2230401/28124/en/Insights-on-the-87-Billion-Cardiovascular-Drugs-Global-Market-to-2030-Identify-Growth-Segments-for-Investment.html (3) https://www.reportlinker.com/p06090622/AntiviralsGlobal-Market-Report-COVID-19-Implications-And-Growth-to.html?utm_source=GNW (4) https://www.thebusinessresearchcompany.com/report/cannabis-products-global-market-report (5) https://www.grandviewresearch.com/industry-analysis/hormonereplacement-therapy-market (6) https://www.fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823 (7) https://www.grandviewresearch.com/industry-analysis/smokeless-tobacco-products-market (8) https://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market (9) https://www.globenewswire.com/en/news-release/2021/05/04/2221987/0/en/Nicotine-Replacement-Therapy-Market-Size-2021-Is-Projected-to-Reach-USD-3-92- Billion-by-2028-Exhibiting-a-CAGR-of-4-3.html (10) https://www.marketdataforecast.com/market-reports/vitamin-d-market NASDAQ:LEXX | NASDAQ:LEXXW Size Future Size Markets US $bn Year US $bn Year CBD(1) 2.7 2021 111.0 2030 Cardiovascular Drugs(2) 87.8 2020 107.8 2025 Antivirals(3) 52.1 2021 66.7 2025 Oral Cannabinoid(4) 18.4 2021 46.2 2025 Human Hormones(5) 21.9 2019 26.8 2022 NSAIDs(6) 15.6 2019 24.4 2027 Oral Mucosal Nicotine(7) 13.6 2018 22.1 2025 PDE5 Inhibitors(8) 4.4 2014 5.3 2022 Nicotine Replacement(9) 2.8 2020 3.9 2028 Vitamin D3(10) 1.1 2021 1.7 202
<< Previous
Bullboard Posts
Next >>